Printer Friendly

CEL-SCI CORPORATION ANNOUNCES THE ADDITION OF A NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD

 ALEXANDRIA, Va., Aug. 10 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ-NMS: CELI) has appointed Dr. Michael J. Mastrangelo to the company's Scientific Advisory Board. Mastrangelo is currently director, division of medical oncology, as well as professor of medicine at Jefferson Medical College in Philadelphia. He has served on the faculties and has held appointments at various medical centers and hospitals. Mastrangelo has been a pioneer in the development of various treatments for malignant melanoma. He has contributed to over 125 publications and several book chapters dealing with the treatment of melanoma.
 Maximilian de Clara, president of CEL-SCI Corporation, commented: "We are extremely pleased to welcome Dr. Mastrangelo to our Scientific Advisory Board. We look forward to the contributions he will make towards the continuing development of our drugs, particularly in the case of malignant melanoma, the fastest growing cancer in the world today."
 CEL-SCI Corporation is the pioneer of combination therapy using lymphokine and cytokine mixtures (Multikine) for the treatment of cancers and immunodeficiencies. Its 50-percent-owned subsidiary, Viral Technologies, Inc., is developing the HGP-30 AIDS vaccine/treatment based on a piece of the "core" protein p17.
 -0- 8/10/93
 /NOTE: Multikine is a trademark./
 /CONTACT: Matthew Haines, director of Investor Relations, CEL-SCI Corporation, 212-996-0608/
 (CELI)


CO: CEL-SCI Corporation ST: Virginia IN: MTC SU: PER

IH-DC -- DC001 -- 1055 08/10/93 08:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1993
Words:221
Previous Article:THE LIMITED, INC. REPORTS SECOND QUARTER SALES INCREASED 13 PERCENT
Next Article:BELMAC APPOINTS FORMER SMITHKLINE BEECHAM EXECUTIVE AS NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters